Related Experiment Video
Updated: Jun 25, 2025
Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
Published on: December 19, 2020
Immunogenicity of Current and Next-Generation Pneumococcal Conjugate Vaccines in Children: Current Challenges and
Kristen Feemster1, Ulrike K Buchwald1, Natalie Banniettis1
1Merck Research Laboratories, Merck & Co, Inc., Rahway, New Jersey, USA.
Insights
Pneumococcal conjugate vaccines (PCVs) reduce disease burden, but higher valency may slightly decrease immunogenicity. Further research is needed to ensure effectiveness of new, broader-coverage PCVs.
Area of Science:
- Immunology
- Vaccinology
- Public Health
Background:
- Pneumococcal conjugate vaccines (PCVs) have significantly reduced pneumococcal disease globally.
- Increasing serotype coverage in PCVs aims to broaden protection against Streptococcus pneumoniae.
Purpose of the Study:
- To evaluate the immunogenicity and effectiveness of higher-valency PCVs.
- To explore strategies for maintaining or improving vaccine effectiveness with broader serotype coverage.
Main Methods:
- Clinical studies comparing different PCVs.
- Assessment of immunoglobulin G geometric mean concentrations and response rates.
- Observational analysis of immunogenicity trends with increasing valency.
Main Results:
- Higher-valency PCVs met noninferiority criteria for most shared serotypes.
- A trend of declining immunogenicity against shared serotypes was observed with higher-valency PCVs.
- The clinical relevance of this immunogenicity trend remains uncertain.
Conclusions:
- While higher-valency PCVs demonstrate noninferiority, potential declines in immunogenicity warrant further investigation.
- Novel approaches in vaccine development (conjugation, carriers, adjuvants, platforms) are crucial for future PCV effectiveness.
- Continued research is essential to optimize PCV design for sustained public health impact.
Abstract:
Global use of pneumococcal conjugate vaccines (PCVs) with increasingly broader serotype coverage has helped to reduce the burden of pneumococcal disease in children and adults. In clinical studies comparing PCVs, higher-valency PCVs have met noninferiority criteria (based on immunoglobulin G geometric mean concentrations and response rates) for most shared serotypes. A numeric trend of declining immunogenicity against shared serotypes with higher-valency PCVs has also been observed; however, the clinical relevance is uncertain, warranting additional research to evaluate the effectiveness of new vaccines. Novel conjugation processes, carriers, adjuvants, and vaccine platforms are approaches that could help maintain or improve immunogenicity and subsequent vaccine effectiveness while achieving broader protection with increasing valency in pneumococcal vaccines.
More Related Videos
13:47Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
Published on: May 19, 2020
08:47Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens
Published on: April 5, 2019
Related Concept Videos
01:51Vaccinations
01:23Immunological Memory
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...
01:22Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
01:26Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and...